Abstract 25P
Background
Breast cancer is the second most common cancer worldwide. Some studies have begun investigation of Absolute Lymphocyte Count (ALC) to predict prognosis of breast metastasis. This review aims to analyze use of ALC to predict overall survival (OS) in breast metastasis patients.
Methods
A total of 73,233 literatures were found through PubMed, PMC, Science Direct, and Google Scholar using a combination of keywords including ALC, breast metastasis, and OS. Publications included are limited to English manuscripts published within the last ten years. We excluded publications with insufficient datas and non-breast metastatic studies. Studies were evaluated by all four authors using the Newcastle-Ottawa Scale (NOS), JADAD scale, funnel plot to assess publication bias, and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) to assess quality of this review.
Results
A total of 11 studies consisting 2,433 patients were included in this review. Nine retrospective studies were of good quality using NOS, two clinical trial studies were of low quality using JADAD scale. GRADE assessment revealed this review to be moderate in quality and publication biases are minimal. Most studies revealed an association between low ALC or lymphopenia and worse prognosis, while 1 study showed otherwise. A pooled analysis of hazard ratio (HR) from log-rank test (HR = 0.57; 95% CI, 0.46-0.71; P = 0.52), univariate cox regression analysis (HR = 0.69; 95%CI, 0.61-0.78; P = 0.01) and multivariate cox regression analysis (HR = 0.70; 95%CI, 0.60-0.81; P = 0.30) showed minimal correlation.
Conclusions
While most studies used in this review showed strong correlation between low ALC and OS with statistically significant results, pooled analysis from this review revealed only the univariate cox regression analysis of HR showed statistically significant results. We conclude that lymphopenia may affect OS in patients with metastatic breast cancer. Further studies are required, especially high quality clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
29P - Targeting CXCR4 promotes antitumor immunity through TOX-mediated CD8+ T cell activation
Presenter: Canhui Cao
Session: Poster viewing 01
30P - Investigation of KRAS G12C inhibitor JAB-21822 as a single agent and in combination with SHP2 inhibitor JAB-3312 in preclinical cancer models
Presenter: Peng Wang
Session: Poster viewing 01
31P - Photothermal responsive, nucleolin-targeted bimetallic nano-vehicle delivered the combinational therapeutics for improved pancreatic cancer treatment
Presenter: Kandasamy Saravanakumar
Session: Poster viewing 01
32P - Tumor growth inhibition effect of PLAG by regulation of neutrophil infiltration in ICI insensitivity B16F10 melanoma
Presenter: Guen Tae Kim
Session: Poster viewing 01
33P - Establishment of personalized therapeutic for salivary gland cancers based on patients-derived salivary tumoroid model
Presenter: Yoonjin Roh
Session: Poster viewing 01
34P - Association of ACRBP gene polymorphism (+26A/G) to liver cancer and diabetes leads to novel biomarker discovery
Presenter: Md Shariful Islam
Session: Poster viewing 01
35P - Exploring plerixafor as a vector molecule in nuclear medicine for targeting CXCR4 receptor overexpression in vivo
Presenter: Tamanna Lakhanpal
Session: Poster viewing 01
36P - Preclinical evaluation of novel MCL-1 degrader in in vitro and in vivo cancer models
Presenter: Piotr Kowalczyk
Session: Poster viewing 01
37P - Development of splice switching antisense oligonucleotides targeting midkine
Presenter: Graham Robertson
Session: Poster viewing 01
38P - Hormonal modulation of photodynamic therapy efficacy in breast cancer 3D spheroid culture model
Presenter: MN Leung
Session: Poster viewing 01